Literature DB >> 20688247

Clinical manifestations and treatment of Wegener's granulomatosis.

Julia U Holle1, Martin Laudien, Wolfgang L Gross.   

Abstract

Wegener's granulomatosis (WG) is characterized by granulomatous lesions and vasculitic disease manifestations. Granulomatous lesions are found in the upper and lower respiratory tract (eg, granulomatous sinusitis, orbital masses, and pulmonary granuloma), whereas vasculitic manifestations occur frequently in lung (alveolar hemorrhage) and kidney (glomerulonephritis). Vasculitis is typically associated with antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3. WG has been traditionally associated with a poor outcome and increased mortality as documented by numerous studies; however, recent cohort studies report an improved outcome, probably a consequence of increased awareness leading to an earlier diagnosis, and to improved treatment strategies derived from evidence from controlled trials. Treatment regimens for WG, adapted to disease stage and activity, are reviewed and discussed in this article. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688247     DOI: 10.1016/j.rdc.2010.05.008

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  17 in total

Review 1.  Histopathologic classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: achievements, limitations, and perspectives.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

2.  Impact of renal involvement on survival in ANCA-associated vasculitis.

Authors:  Manish Rathi; Benzeeta Pinto; Aadhaar Dhooria; Vinay Sagar; Tarun Mittal; Roopa Rajan; Varun Dhir; Susheel Kumar; Kusum Sharma; Ritambhra Nada; Surjit Singh; Ranjana Walker Minz; Aman Sharma
Journal:  Int Urol Nephrol       Date:  2016-06-06       Impact factor: 2.370

3.  Granulomatosis with polyangiitis complicated with bronchopleural fistula.

Authors:  Leyda M Díaz-Correa; Nicolle de León-Tellado; Grissel Ríos; Luis M Vilá
Journal:  BMJ Case Rep       Date:  2014-09-23

4.  Comment to the article "ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity" by Sreih AG et al.

Authors:  Luis Felipe Flores-Suárez; Natllely Ruiz
Journal:  Clin Rheumatol       Date:  2014-09-23       Impact factor: 2.980

Review 5.  Cranial neuropathies in granulomatosis with polyangiitis (Wegener's): a case-based review.

Authors:  Ana Söderström; Sylvie Revaz; Jean Dudler
Journal:  Clin Rheumatol       Date:  2013-12-19       Impact factor: 2.980

6.  Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.

Authors:  Mara Felicetti; Diego Cazzador; Roberto Padoan; Alfonso Luca Pendolino; Chiara Faccioli; Ennio Nardello; Alvise Berti; Marina Silvestrini; Giuseppe Paolazzi; Giuliano Brunori; Elisabetta Zanoletti; Enzo Emanuelli; Alessandro Martini; Franco Schiavon
Journal:  Clin Rheumatol       Date:  2018-02-20       Impact factor: 2.980

7.  Granulomatosis polyangiitis.

Authors:  Mustafa Sowida
Journal:  BMJ Case Rep       Date:  2019-07-08

Review 8.  ANCA-associated vasculitis: report from Korea.

Authors:  Hye Won Kim; Yeong Wook Song
Journal:  Clin Exp Nephrol       Date:  2013-01-05       Impact factor: 2.801

9.  [Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides].

Authors:  S Kleinert; H P Tony
Journal:  Internist (Berl)       Date:  2012-09       Impact factor: 0.743

10.  Alpha 1-antitrypsin activity is markedly decreased in Wegener's granulomatosis.

Authors:  Ali Mota; Abbas Sahebghadam Lotfi; Ahmad-Reza Jamshidi; Saeed Najavand
Journal:  Rheumatol Int       Date:  2013-04-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.